ĐỘC TÍNH CỦA HÓA TRỊ BỔ TRỢ BẰNG PHÁC ĐỒ M-FOLFOX6 TRONG ĐIỀU TRỊ UNG THƯ ĐẠI TRÀNG TẠI BỆNH VIỆN TRUNG ƯƠNG THÁI NGUYÊN

Abstract

Objectives: Descripe toxicity of m-FOLFOX6 therapy regimen as adjuvant chemotherapy for colon cancer in Thai Nguyen Central Hospital. Subjects and methods: Cross-sectional descriptive study on 44 patients colon cancer high risk stage II and III treated at Thai Nguyen Central Hospital from January 2018 to June 2023. Result: mean age of patients: 57,5 ± 9,8, male/female is 1,9. Leukopenia grade 1 were 13,6% after 06 cycles and 9,1% after 12 cycles, 4,5% leukopenia grade 2. Neutropenia grade 1 and 2 after 6 cycles were 15,9% and 9,1% respectively; after 12 cycles were 2,3% và 9,1%. After 06 cycles, no patien had anemia, anemia grade 1 occurred in 4.5% of chemotherapy patients after 12 cycles. Thrombocytopenia grade 1 were 9.1% - 11.4%; grade 2 were 2.3% and 9,1%. Toxicity on liver and kidney were rare. Toxicity on the peripheral nervous system accuonted for 18,2% and 25% after 06 and 12 cycles, mainly grade 1 and 2. Other toxicities such as nausea, vomiting, diarrhea were often grade mild and not recorded grade 3-4. Age and gender were not factors related to the prognosis of neutropenia toxicity and peripheral neurvous in the study subjects. Conclusion: m-FOLFOX6 is an effective regimen as adjuvant treatment of colon cancer and has acceptable toxicity.